TABLE 1.
Basic characteristics of included studies.
| Study | Case (n) | Average age (years) | Gender (Male/female) | Intervening measure | Effectiveness (n) | Course of treatment (days) | Outcome | Publication country | Publication language | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | C | E | C | E | C | E | C | E | C | - | - | - | - | |
| Guan (2018) | 40 | 40 | 56.9 | 44.6 | 32/8 | 30/10 | Ginkgo diterpene lactone meglumine injection | Ginkgo dipyridolum injection | 38 | 31 | 14 | 1, 3 | China | Chinese |
| Lu et al. (2020) | 36 | 36 | 52.2 | 51.8 | 20/16 | 19/17 | Ginkgo diterpene lactone meglumine injection | Aspirin + atorvastatin | - | - | 14 | 2, 3 | China | Chinese |
| Zhu et al. (2019) | 41 | 41 | 65.9 | 63.5 | 28/13 | 29/12 | Ginkgo diterpene lactone meglumine injection | Xueshuantong injection | 40 | 30 | 14 | 1 | China | Chinese |
| Zhang et al. (2018) | 53 | 50 | 62.1 | 61.5 | 38/15 | 35/15 | Ginkgo diterpene lactone meglumine injection | Danhong injection | - | - | 14 | 2, 3 | China | Chinese |
| Jiang et al. (2018) | 50 | 50 | 53.9 | 53.8 | 27/23 | 28/22 | Ginkgo diterpene lactone meglumine injection | Xueshuantong injection | 48 | 41 | 14 | 1, 3 | China | Chinese |
| Zhang et al. (2018) | 43 | 43 | 64.4 | 66.2 | 26/17 | 27/16 | Ginkgo diterpene lactone meglumine injection | Shuxuening injection | 38 | 28 | 14 | 1, 2, 3 | China | Chinese |
| Zhu et al. (2020) | 61 | 66 | 67.2 | 66.6 | 42/19 | 42/24 | Ginkgo diterpene lactone meglumine injection | Dengzhanxixin injection | 57 | 54 | 14 | 1, 2, 3 | China | Chinese |
| Zhou (2020) | 106 | 56 | 64.3 | 62.1 | 60/46 | 39/17 | Ginkgolide injection | Butylphthalide injection | 94 | 49 | 14 | 1, 3 | China | Chinese |
| Feng et al. (2020) | 53 | 53 | 49.6 | 50.1 | - | - | Ginkgo diterpene lactone meglumine injection | Butylphthalide injection | 48 | 45 | 14 | 1, 2 | China | Chinese |
| Ren and Zhao (2006) | 24 | 24 | - | - | 15/9 | 13/11 | Ginkgolide injection | Shuxuening injection | 23 | 21 | 14 | 1 | China | Chinese |
| Zheng (2009) | 30 | 30 | - | - | 16/14 | 17/13 | Ginkgolide B injection | Ginaton injection | 26 | 25 | 14 | 1, 2 | China | Chinese |
| Gu (2008) | 72 | 24 | - | - | - | - | Ginkgolide injection | Shuxuening injection | 63 | 19 | 14 | 1, 3 | China | Chinese |
| Liu (2008) | 24 | 24 | 56.0 | 54.7 | 16/8 | 14/10 | Ginkgolide injection | Shuxuening injection | 22 | 20 | 14 | 1, 2, 3 | China | Chinese |
| Zhao et al. (2013) | 308 | 101 | - | - | - | - | Ginkgo diterpene lactone meglumine injection | Shuxuening injection | 263 | 74 | 14 | 1, 2, 3 | China | Chinese |
| Xia (2014) | 24 | 30 | 58.7 | 62.6 | 18/6 | 18/12 | Ginkgolide injection | Ginkgo leaf extract and dipyridamole injection | 7 | 10 | 14 | 1, 2, 3 | China | Chinese |
| Ji and Cheng (2015) | 32 | 28 | - | - | - | - | Ginkgolide B injection | Compound Danshen injection | 28 | 20 | 14 | 1, 2 | China | Chinese |
| Qiu and Xiao (2015) | 32 | 31 | 57.4 | 56.3 | 19/13 | 17/14 | Ginkgo diterpene lactone meglumine injection | Shuxuening injection | 26 | 22 | 14 | 1, 2, 3 | China | Chinese |
| Gao et al. (2015) | 40 | 40 | 55.4 | 56.2 | 30/10 | 32/8 | Ginkgo diterpene lactone meglumine injection | Ginkgo leaf extract and dipyridamole injection | 38 | 31 | 14 | 1, 2, 3 | China | Chinese |
| Hua (2015) | 120 | 40 | 64.3 | 62.6 | 78/42 | 24/16 | Ginkgo diterpene lactone meglumine injection | Shuxuening injection | 102 | 29 | 14 | 1, 2, 3 | China | Chinese |
| Chen (2016) | 30 | 30 | - | - | - | - | Ginkgo diterpene lactone meglumine injection | Ligustrazine injection | 28 | 25 | 14 | 1 | China | Chinese |
| Zhang (2016) | 66 | 66 | 58.5 | 58.4 | 36/30 | 37/29 | Ginkgolide injection | Ligustrazine injection | 64 | 52 | 14 | 1, 3 | China | Chinese |
| Zhang et al. (2017) | 51 | 50 | 68.2 | 39.8 | 24/37 | 28/22 | Ginkgo diterpene lactone meglumine injection | Shuxuening injection | - | - | 14 | 2 | China | Chinese |
| Lu (2020) | 50 | 50 | 56.2 | 56.2 | 28/22 | 27/23 | Ginkgo diterpene lactone meglumine injection | Xueshuantong injection | 49 | 44 | 14 | 1 | China | Chinese |
| Zhou (2020) | 48 | 48 | 64.1 | 64.3 | 26/22 | 25/23 | Ginkgo diterpene lactone meglumine + rt-PA | rt-PA | - | - | 14 | 2, 3 | China | Chinese |
| Kong et al. (2020) | 54 | 54 | 65.2 | 64.9 | 30/24 | 33/21 | Ginkgo diterpene lactone meglumine + rt-PA | rt-PA | 51 | 43 | 14 | 1, 3 | China | Chinese |
| Zhai et al. (2020) | 78 | 64 | 66.2 | 65.8 | 42/36 | 38/26 | Ginkgo diterpene lactone meglumine + rt-PA | rt-PA | 54 | 31 | 14 | 1, 3 | China | Chinese |
| Zhang et al. (2020) | 45 | 45 | 55.2 | 55.2 | 24/21 | 23/22 | Ginkgo diterpene lactone meglumine + rt-PA | rt-PA | - | - | 14 | 2 | China | Chinese |
| Yu et al. (2021) | 51 | 46 | 65.1 | 64.7 | 27/24 | 24/22 | Ginkgo diterpene lactone meglumine + rt-PA | rt-PA | 45 | 34 | 14 | 1, 2, 3 | China | Chinese |
Note: E, experimental group; C, control group; 1, clinical efficacy; 2, changes of neurological function deficit; 3, ADRs/ADEs, adverse drug reactions/adverse drug events; -, not mentioned.